Pilot production

 – Another big step towards the market 2020 for a diagnostic test for autologous blood doping.

Umeå, Sweden—Ahead of the Tokyo 2020 Olympics, Pro Test Diagnostics (PTD) AB is excited to reach another major milestone in its efforts to deliver a diagnostic kit to detect autologous blood doping.

“We are now even closer to serial production and the introduction on the market, a significant contribution to the fight against autologous blood doping in sports, which to date has no direct test for the practice”, said Anders Mannelqvist, CEO.

PTD has been working diligently with its collaborators, suppliers and partners to produce this first pilot run. The kits were delivered to Pro Test Diagnostics on July 23rd from its ISO certified manufacturing partner (Minerva-Biolabs Gmbh, Berlin).

“We have listened to our collaborators and the pilot production allows Pro Test Diagnostics to work on the final refinement of the kit to enhance the end-user experience at the bench, and ultimately provide a unique test to catch the practice of doping were the athlete’s use their own stored blood to enhance their performance”, according to Nelson Khoo, COO.

We would like to say thank you to our investor, Fort Knox Förvaltning AB for their continued support in our long journey to reach this important point in our company’s history and our vision—Clean Sports Clear Choice.

We look forward to testing our pilot kits with our collaborators and WADA accredited doping control laboratories, Norwegian Doping Control Laboratory at the Oslo University Hospital and Doping Control Laboratory at Karolinska University Hospital in Stockholm.

We are excited to provide future updates as we progress to a market launch in 2020.

Posted by Pro Test Diagnostics, 2019-08-19 in News